MedTrace Logo

Moderate Intensity Aerobic Training in Sub-acute and Chronic Stroke Patients - the Influence on Brain Derived Neurotrophic Factor (BDNF) and Upper-limb Rehabilitation. A Protocol for a Randomized Control Trial and Health Economic Evaluation

NCT03701035 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2022-12-29

No results posted yet for this study

Summary

The aim of this study is to evaluate the influence on three different training modalities on the blood concentration levels of a growth factor called Brain Derived Neurotrophic Factor (BDNF) and on the recovery of arm function following in sub-acute and chronic stroke survivors. The training modalities are 1. moderate intensity aerobic training on a bike ergonometer followed by robotic or sensor-based upper-limb training, 2. non-aerobic circuit training followed by robotic or sensor-based upper-limb training 3. circuit training alone.

Conditions

Interventions

BEHAVIORAL

Aerobic Training & UL Motor Training

Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if \< 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®

BEHAVIORAL

Non-aerobic training & UL Motor Training

40 minutes non-aerobic gait \& balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®

Sponsors & Collaborators

  • Bildungszetrum Gesundheit Basel-Stadt

    collaborator UNKNOWN

  • Rehab Basel

    collaborator OTHER

  • Clare Maguire

    lead OTHER

Principal Investigators

  • Clare Maguire, PhD · Bern University of Applied Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-08
Primary Completion
2020-09-01
Completion
2020-09-01

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03701035 on ClinicalTrials.gov